Validation Of An LCMS Hybrid Assay With EVOSEP Cleanup For The Quantitation Of Islet Amyloid Polypeptide In Human Plasma

Our state-of-the-art LCMS Hybrid Assay delivers highly accurate biomarker analysis, enabling precise quantification of Islet Amyloid Polypeptide (IAPP) in human plasma. This advanced method represents a significant improvement over conventional techniques by integrating plasma immunoprecipitation with EVOSEP solid-phase extraction and microflow chromatography.

By leveraging this innovative combination, the assay achieves detection limits comparable to traditional methodologies while enhancing overall efficiency and reliability. Additionally, the use of a high-binding, non-specific IAPP antibody allows for superior performance compared to commercially available kits, offering a more detailed and comprehensive analysis of various IAPP isoforms. This breakthrough technology provides a valuable tool for research and clinical applications, facilitating a deeper understanding of IAPP-related metabolic processes.